GenePOC to attend ASM in New Orléans, USA from 1-5 June
GenePOC will participate in the ASM (American Society for Microbiology) from June 1 to 5, in New Orleans, Louisiana, USA. Come visit our booth #3004, and discover the new revogene system for...
View ArticleGenePOC announces FDA clearance for revogene™ instrument and its GBS LB test
GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics...
View ArticleGenePOC to attend AACC in San Diego, USA, from July 30-August 3
GenePOC will participate in the AACC (American Association for Clinical Chemistry) from July 30 to August 3, in San Diego, CA, USA. Come visit our booth #533, and discover the new revogene system for...
View ArticleGenePOC to attend ID Week in San Diego, USA, from October 4 to 8
GenePOC will participate in the ID Week from October 4 to 8, in San Diego, CA, USA. Come visit our booth #243, and discover the revogene system for cost-effective, rapid, and accurate molecular...
View ArticleClik here to view.
GenePOC to attend EMMD in Noordwijk, The Netherlands, from October 11th to 13th
GenePOC will participate in the 10th European Meeting of Molecular Diagnostics (EMMD), from October 11th to 13th in Noordwijk aan Zee, The Netherlands. Come visit our booth #6 and discover the revogene...
View ArticleGenePOC to attend AMP in Salt Lake City, UT, USA, from November 16 to 18
GenePOC will participate in the AMP from November 16 to 18, in Salt Lake City, UT, USA. Come visit our booth #1028 , and discover the revogene system for cost-effective, rapid, and accurate molecular...
View ArticleGenePOC announces CE marking of its third assay GenePOC GBS DS
GenePOC has received the CE marking for its third bacteriological test, GenePOC GBS DS, for the direct screening of Group B Streptococcus at intrapartum . Read the entire Press Release her.
View ArticleGenePOC announces FDA clearance for its CDiff test
GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its second molecular assay to detect toxigenic Clostridium difficile. Read the Press Release
View ArticleClik here to view.
GenePOC announces the launch of GenePOC™ GBS LB test and its revogene™...
GenePOC announces it received clearance from Health Canada for GenePOC GBS LB test and its revogene instrument. Read the Press Release
View ArticleMedTech Interview – Innovative companies bring new possibilities for...
GenePOC at the heart of POC testing for infectious diseases – Yole’s MedTech experts Sebastien Clerc and Asma Siari, recently had the opportunity to interview our CEO – Patrice Allibert. They mention...
View Article2017 IDSA Guidelines State the Role of PCR Testing for C. difficile Diagnosis
Clostridium difficile infection (CDI) is the main cause of infectious antibiotic-associated diarrhea with approximately 500,000 infections and $4.8 billion in excess healthcare cost per year in the...
View ArticleClik here to view.
GenePOC Signs Assay Development Contract for Diagnosis of Respiratory...
Under the terms of the services agreement, Primerdesign will develop a triplex molecular diagnostic assay to identify influenza A, influenza B and respiratory syncytial virus A and B (RSV A and B)...
View ArticleGenePOC to attend 28th ECCMID in Madrid, Spain from 21 to 24 April
GenePOC will participate in the 28th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) from April 21 to 24, in Madrid, Spain. Come visit our booth #40 – Discover the power of...
View ArticlePractical Patient Care Interview – Infection test for expectant mother
Practical Patient Care talks to Dr Mayra Bermudez Martinez, an obstetrician in the Klinik für Gynäkologie und Geburtshilfe at the Hochst Klinikum in Frankfurt, about the importance of timely screening...
View ArticleGenePOC to attend ASM in Atlanta, USA from 7 to 11 June 2018
GenePOC will participate in the ASM (American Society for Microbiology) from June 7 to 11, in Atlanta, USA. Come visit our booth #1420 – Discover the power of the PIE and revogene instrument for...
View ArticleGenePOC to attend ID Week in San Francisco, USA from 3 to 7 of October 2018
Come visit our booth #1204 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
View ArticleGenePOC to attend AMP in San Antonio, USA from 31 of October to 3 of November...
Come visit our booth #1629 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
View ArticleGENEPOC ANNOUNCES HEALTH CANADA APPROVAL OF ITS CDIFF TEST
Read the Press Release here.
View ArticleGenePOC’s Investment in SMRT Panels Validated by Medicare Decision
Read the entire Genomeweb interview to learn more on GenePOC’s vision, future SMRT Panels (Specific, Medically appropriate, Reimbursement appropriate Test) in alignment with the Palmetto decision, and...
View ArticleGenePOC to attend MEDLAB in Dubai from February 4-7 2019
Come visit our booth # Z3 C33 – Discover the power of the PIE and revogene instrument for molecular detection of infectious diseases.
View Article
